References: 1. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: a clinical practice guideline. http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Published 2014. Accessed May 18, 2016. 2. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Published July 2015. Accessed May 9, 2016. 3. Centers for Disease Control and Prevention. Condom effectiveness. http://www.cdc.gov/condomeffectiveness/. Published 2016. Accessed May 17, 2016. 4. Centers for Disease Control and Prevention. Testing. http://www.cdc.gov/hiv/basics/testing.html/Should. Published 2016. Accessed April 27, 2016. 5. Centers for Disease Control and Prevention. Prevention benefits of HIV treatment. http://www.cdc.gov/hiv/research/biomedicalresearch/tap/index.html. Published 2016. Accessed April 27, 2016. 6. Centers for Disease Control and Prevention. HIV risk reduction tool: sharing needles or works? https://wwwn.cdc.gov/hivrisk/increased_risk/sharing_needles.html. Accessed April 27, 2016. 7. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health
approach—second edition. http://www.who.int/hiv/pub/arv/arv-2016/en/. Published June 2016. Accessed June 27, 2016. 8. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. https://stacks.cdc.gov/view/cdc/38856. Published 2016. Accessed May 18, 2016. 9. AIDS.gov. Post-exposure prophylaxis (PEP). https://www.aids.gov/hiv-aids-basics/prevention/reduce-your-risk/post-exposure-prophylaxis/. Published September 21, 2015. Accessed June 1, 2016. 10. Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):390-409. doi:10.1001/jama.2014.7999.